9OED

Ab1999 in complex with HIV-1 Env RC1

これはPDB形式変換不可エントリーです。

9OED の概要

• エントリーDOI: 10.2210/pdb9oed/pdb
• 関連するPDBエントリー: 9O8M
• EMDBエントリー: 70395
• 分子名称: Ab1999 Fab Heavy Chain variable region, Ab1999 Fab Light Chain variable region, Envelope glycoprotein gp120, ... (9 entities in total)
• 機能のキーワード: hiv-1 env, antibody, viral protein
• 由来する生物種: Macaca mulatta (Rhesus monkey); 詳細
• タンパク質・核酸の鎖数: 8
• 化学式量合計: 253559.22

構造登録者

Lin, Z.J.,Cui, J.,Du, J.,Relano-Rodriguez, I.,Escolano, A.,Pallesen, J. (登録日: 2025-04-28, 公開日: 2026-02-11)

主引用文献

Relano-Rodriguez, I.,Du, J.,Lin, Z.J.,Kerwin, M.,Tarquis-Medina, M.,Urbano, E.,Cui, J.,Watkins, M.,Lavine, C.L.,Zhao, P.,Habib, R.,Agostino, C.,Ghosh, S.,Park, J.,Boroughs, C.,Walsh, A.A.,Melo, M.B.,Shukla, N.,Shaw, G.M.,Hahn, B.H.,Irvine, D.J.,Wells, L.,Weiner, D.B.,Seaman, M.S.,Kulp, D.W.,Veazey, R.S.,Pallesen, J.,Escolano, A.
Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates.
Nat.Immunol., 2026

PubMed Abstract: Sequential immunization is a promising approach to elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 Envelope (Env). However, available protocols are inefficient and involve multiple immunizations over long periods of time. Here, we present WIN332, a new engineered Env immunogen that induces a new class of Asn332-glycan-independent antibodies to the conserved V3-glycan epitope of Env with low inhibitory activity indicative of a neutralization activity after a single bolus immunization in nonhuman primates. WIN332 binds to precursors of canonical human Asn332-glycan-dependent (type-I) V3-glycan bNAbs but also of a first-of-its-class Asn332-glycan-independent (type-II) V3-glycan bNAb. A single immunization elicits low inhibitory serum and monoclonal antibodies that are boosted and affinity matured with a heterologous immunogen. Electron microscopy polyclonal epitope mapping analysis of serum antibodies, antibody cloning and cryogenic electron microscopy analysis reveals that WIN332 elicits Asn332-glycan-independent antibodies with striking sequence and binding similarities with the most potent human type-I and type-II V3-glycan bNAbs. Thus, WIN332 is a promising vaccine candidate to streamline V3-glycan bNAb elicitation.

PubMed: 41634485
DOI: 10.1038/s41590-025-02408-z

実験手法

ELECTRON MICROSCOPY (3.94 Å)